Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oxurion NVLTS:0G99 9 EV-to-EBITDA is -3.20 as of Aug. 29, 2026. GuruFocus rates LTS:0G99 with a GF Score™ of 9/100 and a GF Value™ of €0.98. The stock has 7 warning signs investors should review. Among 414 Biotechnology companies, Oxurion NV ranks worse than 241545.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oxurion NV's enterprise value is €11.58 Mil.
Oxurion NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.62 Mil. Therefore, Oxurion NV's EV-to-EBITDA for today is -3.20.
The historical rank and industry rank for Oxurion NV's EV-to-EBITDA or its related term are showing as below:
LTS:0G99'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.61 Med: -0.66 Max: 40.23
Current: -3.2
During the past 13 years, the highest EV-to-EBITDA of Oxurion NV was 40.23. The lowest was -4.61. And the median was -0.66.
LTS:0G99's EV-to-EBITDA is ranked worse than 100% of 414
companies
in the Biotechnology industry
Industry Median: 13.55
vs LTS:0G99: -3.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oxurion NV's share price for today is €0.273.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxurion NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.281.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Oxurion NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0G99 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Oxurion NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxurion NV EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxurion NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oxurion NV's EV-to-EBITDA falls into.
Oxurion NV's current Enterprise Value is €11.58 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxurion NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxurion NV (LTS:0G99) has a EV-to-EBITDA of -3.20 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oxurion NV. According to the industry distribution chart, Oxurion NV ranks #999999 out of 414 companies in the Biotechnology industry.
Is Oxurion NV's EV-to-EBITDA too high?
Oxurion NV's current EV-to-EBITDA is -3.20. Based on the distribution chart, Oxurion NV ranks #999999 out of 414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxurion NV has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Oxurion NV's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxurion NV ranks #999999 out of 414 companies for EV-to-EBITDA. This places Oxurion NV in the lower half of its industry. The industry median EV-to-EBITDA is 13.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.55, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oxurion NV. For the Biotechnology industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxurion NV's current EV-to-EBITDA is -3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxurion NV stock overvalued right now?
Oxurion NV (LTS:0G99) has a current EV-to-EBITDA of -3.20. The stock's GF Value™ is €0.98, compared to a current price of €0.27 — trading 72.1% below its estimated fair value. The current EV-to-EBITDA is -3.20. Oxurion NV's overall GF Score™ is 9/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Oxurion NV (LTS:0G99), the current EV-to-EBITDA is -3.20 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxurion NV (LTS:0G99) Overvalued in 2026?
Based on GuruFocus' analysis, Oxurion NV stock appears to be undervalued.
The current stock price of €0.27 is trading 72.1% below its estimated GF Value™ of €0.98.
Key valuation signals for LTS:0G99:
EV-to-EBITDA: -3.20
GF Value™: €0.98 vs. price of €0.27 (72.1% below fair value)
No single metric tells the full story. See the LTS:0G99 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.
9GF Score
Get the complete analysis for LTS:0G99
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0G99 has been successfully added to your 
